权威期刊重磅研究！司美格鲁肽等GLP-1药物可延缓衰老，显著降低死亡率

Core Viewpoint - Semaglutide can improve health and slow the aging process, with studies indicating a reduction in mortality rates from various causes, including cardiovascular diseases and COVID-19 [2][4]. Research Background - The prevalence of obesity has led to an increase in obesity-related complications and overall mortality rates. Obesity is an independent risk factor for cardiovascular mortality, making it challenging to reduce obesity-related death rates due to the limited availability of effective interventions [5]. Study Findings - In the SELECT trial, semaglutide significantly reduced all-cause mortality compared to the placebo group, with a 19% reduction in all-cause mortality, a 15% reduction in cardiovascular mortality, and a 23% reduction in non-cardiovascular mortality for overweight or obese patients with cardiovascular disease [10][16]. - Among the deaths recorded, 58% were due to cardiovascular causes, while 42% were non-cardiovascular. The most common causes of cardiovascular death were sudden cardiac death, while infections (including COVID-19) and malignancies were the leading causes of non-cardiovascular death [10][11]. COVID-19 Impact - The use of semaglutide did not reduce the incidence of COVID-19 among patients, but it significantly lowered the mortality rate associated with COVID-19, reducing the risk of death from COVID-19 by one-third [4][15]. The mortality rate for patients using semaglutide was 2.6%, compared to 3.1% for those on placebo [15]. Conclusion - The findings emphasize the benefits of semaglutide in reducing mortality rates among overweight or obese patients with cardiovascular disease. The reduction in non-cardiovascular deaths is primarily attributed to decreased mortality from infections, particularly COVID-19, rather than a general decrease in all non-cardiovascular causes of death [16].